PLAVIX DEAL STOKES PHARMA STOCKS, BIOGEN WEIGHS ON BIOTECH

News that Bristol-Myers Squibb and partner Sanofi-Aventis may have successfully warded off early generic competition for their blockbuster drug Plavix stoked trading of pharmaceutical stocks early Wednesday. Biotech issues, however, slid into negative territory, burdened by news that the FDA is delaying a formal decision on whether to allow Biogen Idec's recalled drug Tysabri back on the market.

MarketWatch (http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B5F207F46%2D492C%2D438F%2D8A7A%2DBFBD48A05237%7D&siteid=google)